KEYTRUDA® (pembrolizumab) in locally advanced unresectable or metastatic oesophageal cancer

KEYTRUDA in combination with platinum and fluoropyrimidine-based chemotherapy is indicated for:

	Locally advanced unresectable or metastatic oesophageal cancer
For use in	The first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or human epidermal growth factor receptor 2 (HER2)-negative gastroesophageal junction (GEJ) adenocarcinoma in adults whose tumours express PD-L1 Combined Positive Score (CPS) ≥10.¹
Dosing schedule	The recommended dose is either 200 mg every 3 weeks or 400 mg every 6 weeks, administered as an intravenous infusion over 30 minutes¹
Duration of treatment	Treat until disease progression or unacceptable toxicity¹
Clinical trial	KEYNOTE-590 was a Phase 3, multicentre, double-blind, active-controlled study of adult patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or human epidermal growth factor receptor 2 (HER2)-negative gastroesophageal junction (GEJ) adenocarcinoma, randomised 1:1 to receive pembrolizumab + cisplatin + 5-FU (fluorouracil) or placebo + cisplatin + 5-FU¹ Click here to download the KEYNOTE-590 clinical data presentation Download

Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.